Prosecution Insights
Last updated: July 17, 2026
Application No. 18/681,103

AROMATIC ACETYLENE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Non-Final OA §103§112
Filed
Feb 05, 2024
Priority
Aug 05, 2021 — CN 202110893728.1 +2 more
Examiner
HEASLEY, MEGHAN CHRISTINE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shanghai Aryl Pharmtech Co. Ltd.
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
7m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
96 granted / 124 resolved
+17.4% vs TC avg
Strong +32% interview lift
Without
With
+32.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
61 currently pending
Career history
162
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
47.0%
+7.0% vs TC avg
§102
21.0%
-19.0% vs TC avg
§112
12.2%
-27.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 124 resolved cases

Office Action

§103 §112
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-17 are pending. Claims 2, 4, 7-8, 11-13, and 15-17 are withdrawn. Claims 1, 3, 5-6, 9, and 14 are rejected. Claim 10 is objected to. Information Disclosure Statement The Information Disclosure Statements (IDS’s) submitted on 2/5/2024, 4/10/2025, and 10/8/2025 were considered by the Examiner. Priority This is a 35 U.S.C. 371 National Stage Filing of International Application No. PNG media_image1.png 22 207 media_image1.png Greyscale , which claims priority under 35 U.S.C. 119(a-d) to PNG media_image2.png 40 231 media_image2.png Greyscale . Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d). Election/Restrictions Applicant’s election of Group I and the species Example 59: PNG media_image3.png 339 483 media_image3.png Greyscale , which is embraced by a compound of formula (A-I) of instant claim 1: PNG media_image4.png 149 334 media_image4.png Greyscale , wherein R4 = PNG media_image5.png 44 58 media_image5.png Greyscale , q = 1; ring B = PNG media_image6.png 45 50 media_image6.png Greyscale ; L1 = -CH2-; ring A = PNG media_image7.png 47 46 media_image7.png Greyscale ; Q = C; V, X, Y = C; Z = N; R1 = -G1-R5, m = 1, G1 = -CH2-; R5 = -NR12R13, R12 = H; R13 = alkyl substituted with PNG media_image8.png 59 55 media_image8.png Greyscale , R9 = alkyl; in the reply filed on 5/10/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 1, 3, 5, 6, 9, 10, and 14 embrace Applicant’s elected species and are therefore under examination. The elected species is free of the prior art. As per MPEP 803.02, “Following election, the Markush claim will be examined fully with respect to the elected species and further to the extent necessary to determine patentability.” A non-elected species has been found incidental to the search of the elected species and rejected below in the interest of compact prosecution. Additionally, claims 3, 5, 9, and 10 have been searched in full and are free of the prior art. Claims 2, 4, 7-8, 11-13, and 15-17 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claim Objections Claim 1 is objected to because of the following informalities: the word “consisting” is misspelled numerous times (see p. 2, last line, p. 3, lines 1, 4, 8-9, 13, 21, 27). Appropriate correction is required. Claim 10 should have commas between each compound. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 3, 5-6, 9 and 14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the phrase “preferably" (three locations: p. 2, line 5 and 5th from bottom line and p. 4, fourth from bottom line) renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Examiner recommends deleting this phrase. Claims 3, 5-6, 9 and 14 are additionally rejected for depending from claim 1 and failing to remedy its deficiencies. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 6, and 14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Hefferman et al. (WO2012162635-disclosed on 2/5/2024 IDS). Determining the scope and contents of the prior art. (See MPEP § 2141.01) Hefferman et al. disclose the following compound 38 on p. 83: PNG media_image9.png 140 238 media_image9.png Greyscale . Hefferman additionally discloses the following on p. 5, line 3-5: PNG media_image10.png 83 577 media_image10.png Greyscale . Ascertainment of the differences between the prior art and the claims. (See MPEP § 2141.02) The prior art compound shown supra differs from a compound of the instant claims in that q = 0 (the instant claims allow for “q = 1, 2, or 3”). Finding of prima facie obviousness --- rationale and motivation (See MPEP § 2142-2143) Regarding instant claims 1, 6, and 14, the prior art compound shown supra is similar to a compound of instant formula (A-1): PNG media_image4.png 149 334 media_image4.png Greyscale wherein V, X, Y, Z = C; R1 = single bond-halogen (F), m = 1; Q = C; A = PNG media_image11.png 41 38 media_image11.png Greyscale , n = 0, p = 0; L1 = -CH2-; ring B = PNG media_image12.png 47 40 media_image12.png Greyscale . At the location of the instant “R4” are only hydrogen’s wherein the instant claims teach that this location may be alkyl. Alkyl includes methyl. The compounds as taught by the prior art and the compounds in the instant claims are considered structural analogs and hydrogen and methyl are deemed obvious variants. It is well established that the substitution of hydrogen for methyl on a known compound is not a patentable modification absent unexpected or unobvious results. In re Wood, Whittaker, Stirling, and Ohta, 582 F.2d 638, 199 U.S.P.Q 137 (C.C.P.A. 1978). In the instant case, a person having ordinary skill in the art at the time the invention was filed would have been motivated to synthesize the instantly claimed analogs with the reasonable expectation that it would have the same utility as the closest structurally related compounds taught by the prior art and with the motivation of obtaining additional useful compounds. A person of ordinary skill in the art would have expected them to be useful in the same utilities and been motivated to apply them in the same methods. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGHAN C HEASLEY whose telephone number is (571)270-0785. The examiner can normally be reached Monday - Friday 8:30-4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGHAN C HEASLEY/Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Feb 05, 2024
Application Filed
Jun 03, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678428
A SYNERGISTIC COMPOSITION FOR INHIBITING VASCULAR CALCIFICATION
2y 7m to grant Granted Jul 14, 2026
Patent 12655145
P2X3 MODULATORS
3y 10m to grant Granted Jun 16, 2026
Patent 12655127
FUSED RING COMPOUND AS WEE-1 INHIBITOR
2y 10m to grant Granted Jun 16, 2026
Patent 12637432
INHIBITORS OF ACK1/TNK2 TYROSINE KINASE
3y 3m to grant Granted May 26, 2026
Patent 12630564
INTERNAL CYCLIC SULPHIAMIDINE AMIDE-ARYL AMIDE COMPOUND AND USE THEREOF FOR TREATING HEPATITIS B
3y 10m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+32.2%)
3y 1m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 124 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month